About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Profile
Schools
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Scientometrics
Avg Impact Factor
h-index
g-index
★★
Articles
★★★
Articles
exaly
›
Institutions
›
Tufts Center for the Study of Drug Development
›
Top Articles
Tufts Center for the Study of Drug Development
United States of America
(csdd.tufts.edu)
241
(top 24%)
articles
11.7K
(top 15%)
citations
53
(top 21%)
★★
articles
8
(top 10%)
★★★
articles
2.7
(top 17%)
Avg IF
40
(top 18%)
H-Index
106
(top 12%)
G-Index
76
journals
Most Cited Articles of Tufts Center for the Study of Drug Development in 2013
Title
Journal
Year
Citations
Clinical approval success rates for investigational cancer drugs
Clinical Pharmacology and Therapeutics
2013
126
Clinical and economic challenges facing pharmacogenomics
Pharmacogenomics Journal
2013
45
Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration
Oncologist
2013
26
Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications
Clinical Therapeutics
2013
24
Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future development
Journal of Medical Economics
2013
9
New Governance Mechanisms to Optimize Protocol Design
Therapeutic Innovation and Regulatory Science
2013
9
Benchmarking the Study Initiation Process
Therapeutic Innovation and Regulatory Science
2013
8
Economic impact of a triptan Rx-to-OTC switch in six EU countries
PLoS ONE
2013
8
Is the increasing cost of treating rare diseases sustainable?
Expert Opinion on Orphan Drugs
2013
5
Impact of In-Pharmacy Education on Patients' Knowledge and Attitudes About Clinical Trials
Therapeutic Innovation and Regulatory Science
2013
3
site/software ©
exaly
; All materials licenced under
CC by-SA
.